Key facts
- MabGenesis’s last known valuation is $18.6M (Dec 2024).
- It has raised $8.8M; the latest was Later Stage VC ($3.1M) in Dec 2024.
- Notable investors include SMBC Venture Capital, Beyond Next Ventures, Regional Economy Vitalization Corporation of Japan, REVIC Capital, Anniversaire Holdings — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for MabGenesis
- ·The full record, as it builds
Funding rounds
No funding rounds for MabGenesis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MabGenesis
Operator of a biopharmaceutical company intended to develop therapeutic monoclonal antibody drugs for humans and animals. The company specializes in discovering fully human and canine/feline therapeutic antibodies for humans and animals that can be licensed to pharmaceutical companies, providing the healthcare and pharmaceutical industry with new drug development opportunities.
- Sector
- Healthcare
- HQ
- Yokohama, Japan
- Founded
- 2019
- Website
- mabgenesis.com/
- Ownership
- Privately Held (backing)
MabGenesis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MabGenesis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MabGenesis in its N-PORT filings yet. We sweep new filings monthly.